TRIP10

Across TCGA pan-cancer cohorts, TRIP10 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TRIP10 data layer compared with 30 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRIP10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRIP10 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where TRIP10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.514	0.860	.004	17	view →
GBM	DFS	Median	All	0.644	0.847	.002	16	view →
LUAD	OS	Quartile	III,IV	0.354	0.872	.015	12	view →
HNSC	OS	Tertile	All	1.000	0.270	.014	11	view →
UCEC	DFS	Median	All	0.962	0.847	.022	8	view →
COAD	DFS	Median	III,IV	1.000	0.844	.044	6	view →
PDAC	DFS	Median	II,III,IV	0.304	0.513	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TRIP10–CCRCC (DFS)

Open the CCRCC breakdown →